Cancer Killers

Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board

Hamilton, ON & Boston, MA – January 13, 2020 – Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an investment commitment of up to US$20 million from Canada Pension Plan Investment Board (CPPIB).  CPPIB joins Fusion’s existing group of top-tier investors adding to the US$105 million Series B announced in April 2019.

The financing will primarily be used to expand the use of the Company’s Fast-ClearTM Linker Technology platform by investing in new partnerships and targeting molecules to create novel targeted alpha therapeutics, and to continue to advance its lead asset, FPI-1434, currently in a Phase 1 trial for treating solid tumors.

“Fusion is delighted to welcome the support of CPPIB, and to add another prominent institution to our highly regarded investor base,” said Chief Executive Officer John Valliant.  “CPPIB’s investment reflects strong support for Fusion’s platform technology and people and demonstrates momentum in the radiopharmaceutical industry.  The additional capital provides opportunities for Fusion to accelerate our growth plans and our pipeline of novel and combination therapy assets that can deliver effective and personalized radiation therapies to cancer patients.”

Ends.

About Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapeutics to treat cancer.  Using its proprietary Fast-Clear™ Linker Technology platform, Fusion attaches medical isotopes to targeting molecules creating novel, next-generation cancer treatments.  In preclinical studies, the Company has shown the ability to precisely target and effectively kill solid tumor cells while minimizing the impact to healthy tissue.  Fusion’s lead program, FPI-1434, is currently in a Phase 1 trial.  With a proprietary discovery platform, Fusion is actively in-licensing targeting molecules and forming strategic partnerships to expand its pipeline of cancer therapies.  For more information, please visit www.fusionpharma.com

For further information, please contact Vicky La Touche-Price at Seroba on +35316334028.

 

Recent Articles

STORM Therapeutics Logo

STORM Therapeutics selects first-in-class clinical candidate targeting METTL3

22 October 2020, Cambridge, UK: Seroba’s investee company, STORM Therapeutics, the leading biotechnology company focused on the discovery and development […]

Read More
STORM Therapeutics Logo

FutureNeuro partners with STORM Therapeutics to explore the role of RNA epigenetics in epilepsy.

Dublin, Ireland.  9 September 2020.  FutureNeuro has announced that it has entered into partnership with Seroba’s portfolio company, STORM Therapeutics, […]

Read More
Pq Bypass

PQ Bypass Receives FDA “Breakthrough Device Designation” for the World’s First Fully Percutaneous Femoral-Popliteal Bypass Device.

MILPITAS, Calif. – September 2, 2020 – PQ Bypass Inc, a medical device pioneer bringing new advancements to the treatment […]

Read More
Susan Trent Photo

Atlantic Therapeutics appoints Susan Trent as new CEO, based in the United States.

Galway, Ireland.   Seroba’s portfolio company, Atlantic Therapeutics, a Galway-based MedTech and Femtech innovator, announces a transition in leadership to fulfill […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top